Cancer Immunotherapy, Part 3: Challenges and Future Trends – P&T Community
|
Cancer Immunotherapy, Part 3: Challenges and Future Trends
P&T Community One major limitation of cancer immunotherapy is the availability of known targetable tumor-specific antigens (TSAs), also called “neoantigens,” that are solely expressed by tumor cells. Tumor-associated antigens, which are expressed by both tumor and … |
